Literature DB >> 10929045

Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin.

H Ninomiya1, Y Kawashima, T Nagasawa.   

Abstract

Complement (C')-mediated haemolysis in paroxysmal nocturnal haemoglobinuria (PNH) is mainly due to the deficiency of glycosyl phosphatidylinositol-anchored membrane proteins with C'-regulatory activities CD55 and CD59 in PNH-affected red blood cells (RBCs). Hydrophobic insertion of C5b-7 to RBC membranes, initiating the formation of a membrane attack complex, readily results in lysis of PNH RBCs due to the deficiency of CD59. We studied the significance of the electrostatic interactions between C5b-6 and RBC membranes preceding the insertion of C5b-7. In vitro, C'-mediated lysis of PNH RBCs (assessed by sucrose haemolytic assay) was inhibited by heparin, low-molecular weight heparin (LMWH) or protamine, indicating the significance of the electrostatic interactions between C' components and RBC membranes in the process of C'-mediated haemolysis. Neuraminidase-treated PNH RBCs became resistant to C' activation, suggesting that the sialic acid moieties on RBC membranes are involved in the interactions of RBC with C' components. By using biotin-labelled C7, we demonstrated that LMWH as well as heparin inhibited the insertion of C5b-7 to RBCs, although they did not inhibit the incorporation of C7 into membrane-associated C5b-6. Neither heparin nor LMWH could inhibit the procoagulant alteration of PNH RBC membranes induced by C' activation even at concentrations which inhibited the haemolysis completely. Because LMWH inhibited the C'-mediated lysis of PNH RBCs in vitro at the range which induced a limited prolongation of activated partial thromboplastin time of normal plasma, we consider that LMWH may be useful for both the inhibition of haemolysis and the prevention of thrombosis, which often follow a haemolytic attack in PNH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929045     DOI: 10.1046/j.1365-2141.2000.02125.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Management issues in paroxysmal nocturnal hemoglobinuria.

Authors:  Gabrielle Meyers; Charles J Parker
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

2.  Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.

Authors:  Jaime M Shamonki; Jane E Salmon; Elizabeth Hyjek; Rebecca N Baergen
Journal:  Am J Obstet Gynecol       Date:  2007-02       Impact factor: 8.661

3.  Microvascular thrombosis in the hepatic vein of a patient with paroxysmal nocturnal hemoglobinuria.

Authors:  Hideyoshi Noji; Tsutomu Shichishima; Masatoshi Okamoto; Akiko Shichishima-Nakamura; Hayato Matsumoto; Hiroko Tajima; Kazuei Ogawa; Yukio Maruyama
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

Review 4.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

5.  Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Benjamin L Shneider; Jonathan S Bromberg; Patricia A Shi; Stephen C Ward; Margret S Magid; Corinne Benchimol; Mouin G Seikaly; Sukru H Emre; Elena Bresin; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 8.237

6.  A patient with paroxysmal nocturnal hemoglobinuria being treated with eculizumab who underwent laparoscopic cholecystectomy: report of a case.

Authors:  Makoto Moriyama; Takuya Nagata; Isaku Yoshioka; Isaya Hashimoto; Koshi Matsui; Tomoyuki Okumura; Kazuhiro Tsukada
Journal:  Surg Case Rep       Date:  2015-07-11

Review 7.  How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.

Authors:  Antonio Maria Risitano; Régis Peffault de Latour
Journal:  Br J Haematol       Date:  2021-08-05       Impact factor: 8.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.